^
Association details:
| Biomarker: | MELTF overexpression |
|---|---|
| Cancer: | Triple Negative Breast Cancer |
| Drug: | SGN-CD228A (Microtubule inhibitor, CD228-targeted antibody-drug conjugate) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
SGN-CD228A Is an Investigational CD228-Directed Antibody-Drug Conjugate with Potent Antitumor Activity across a Wide Spectrum of Preclinical Solid Tumor Models
Published date:
04/03/2023
Excerpt:
Similarly, SGN-CD228A produced a high response rate in TNBC (59% ORR, all models), which improved to 78% ORR in high CD228-expressing models (n = 9) compared with 46% ORR (n = 13) in low-expressing models….Overall, SGN-CD228A is a CD228-directed, investigational ADC that employs innovative technology and has compelling preclinical antitumor activity.
DOI:
10.1158/1535-7163.MCT-22-0401
Source:
Title:
Abstract 2688: SGN-CD228A: A novel humanized anti-CD228 antibody-drug conjugate for the treatment of solid tumors
Excerpt:
Additionally, in a mouse TNBC PDX clinical trial (n=22), we found that SGN-CD228A achieved durable CRs even in low expressing PDX models. In summary, CD228 is a highly expressed carcinoma target and the novel glucuronide-MMAE ADC, SGN-CD228A, shows potent antitumor activity in vitro and in vivo.
DOI:
10.1158/1538-7445.AM2019-2688
